This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:publications:marshall_days_of_molecular_medicine_2007 [04.21.2009] – external edit 127.0.0.1 | home:publications:marshall_days_of_molecular_medicine_2007 [09.03.2010] – external 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
+ | | ||
+ | **Type:** Poster presentation\\ | ||
+ | **Presenter: | ||
+ | **Conference: | ||
+ | **Location: | ||
+ | **Date: | ||
+ | **Additional content:** [[http:// | ||
+ | |||
+ | ===== Abstract ===== | ||
+ | |||
+ | The US FDA currently accepts carcinogenicity studies of pharmaceutical drugs based on murine models. In addition to 6 month studies with p53(+/-) and ras.H2 transgenic mice, lifetime studies (typically 2 years) in WT mice or rats are also considered as evidence that a drug lacks carcinogenic activity. This model is not always exhaustive. For example, during the acceptance testing of the ARB Olmesartan((FDA CDER: NDA-21-286, Sankyo Pharma Inc. Available from: | ||
+ | http:// | ||
+ | Chronic Inflammatory and Autoimmune Disease. Abstract presentation, | ||
+ | |||
+ | ==== Conclusion ==== | ||
+ | |||
+ | The murine environment is inadequate to accurately model drug carcinogenic activity in humans. A species should be chosen which has a VDR LBP homology closer to that of man. AutoDock and GROMACS molecular analyses are useful in resolving any remaining anomalies in the observed data. | ||
+ | |||
+ | {{tag> | ||
+ | |||
+ | |||
+ | ===== References ===== |